Since the involvement of both CD4+ and CD8+ T cells is suggested for optimal protection against mycobacterial disease [49], [50], the use of crossreactive peptide 121-VLTATNFFGINTIPIALTEMDYFIR-145 of PPE68 may be useful as a peptide-based vaccine against TB and other mycobacterial diseases. The gene discussed is CD4; the disease is tuberculosis.